Disrupted cerebral metabolite levels and lower nadir CD4+ counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatmentpatients on stable treatment

AbstractCognitive impairment and brain injury are common in people with HIV/AIDS, even when viral replication is effectively suppressed with combined antiretroviral therapies (cART). Metabolic and structural abnormalities may promote cognitive decline, but we know little about how these measures relate in people on stable cART. Here we used tensor-based morphometry (TBM) to reveal the 3D profile of regional brain volume variations in 210 HIV+ patients scanned with whole-brain MRI at 1.5T (mean age: 48.6±8.4years; all receiving cART). We identified brain regions where the degree of atrophy was related to HIV clinical measures and cerebral metabolite levels assessed with magnetic resonance spectroscopy (MRS). Regional brain volume reduction was linked to lower nadir CD4+ count, with a 1–2% white matter volume reduction for each 25-point reduction in nadir CD4+. Even so, brain volume measured by TBM showed no detectable association with current CD4+ count, AIDS Dementia Complex (ADC) stage, HIV RNA load in plasma or cerebrospinal fluid (CSF), duration of HIV infection, antiretroviral CNS penetration-effectiveness (CPE) scores, or years on cART, after controlling for demographic factors, and for multiple comparisons. Elevated glutamate and glutamine (Glx) and lower N-acetylaspartate (NAA) in the frontal white matter, basal ganglia, and mid frontal cortex — were associated with lower white matter, putamen and thalamus volumes, and ventricular and CSF space expansion. Reductions in brain volumes in the setting of chronic and stable disease are strongly linked to a history of immunosuppression, suggesting that delays in initiating cART may result in imminent and irreversible brain damage

Neuroimaging study designs, computational analyses and data provenance using the LONI pipeline.

Modern computational neuroscience employs diverse software tools and multidisciplinary expertise to analyze heterogeneous brain data. The classical problems of gathering meaningful data, fitting specific models, and discovering appropriate analysis and visualization tools give way to a new class of computational challenges--management of large and incongruous data, integration and interoperability of computational resources, and data provenance. We designed, implemented and validated a new paradigm for addressing these challenges in the neuroimaging field. Our solution is based on the LONI Pipeline environment [3], [4], a graphical workflow environment for constructing and executing complex data processing protocols. We developed study-design, database and visual language programming functionalities within the LONI Pipeline that enable the construction of complete, elaborate and robust graphical workflows for analyzing neuroimaging and other data. These workflows facilitate open sharing and communication of data and metadata, concrete processing protocols, result validation, and study replication among different investigators and research groups. The LONI Pipeline features include distributed grid-enabled infrastructure, virtualized execution environment, efficient integration, data provenance, validation and distribution of new computational tools, automated data format conversion, and an intuitive graphical user interface. We demonstrate the new LONI Pipeline features using large scale neuroimaging studies based on data from the International Consortium for Brain Mapping [5] and the Alzheimer's Disease Neuroimaging Initiative [6]. User guides, forums, instructions and downloads of the LONI Pipeline environment are available at http://pipeline.loni.ucla.edu

Neuroimaging biomarkers of neurodegenerative diseases and dementia

Neurodegenerative disorders leading to dementia are common diseases that affect many older and some young adults. Neuroimaging methods are important tools for assessing and monitoring pathological brain changes associated with progressive neurodegenerative conditions. In this review, the authors describe key findings from neuroimaging studies (magnetic resonance imaging and radionucleotide imaging) in neurodegenerative disorders, including Alzheimer's disease (AD) and prodromal stages, familial and atypical AD syndromes, frontotemporal dementia, amyotrophic lateral sclerosis with and without dementia, Parkinson's disease with and without dementia, dementia with Lewy bodies, Huntington's disease, multiple sclerosis, HIV-associated neurocognitive disorder, and prion protein associated diseases (i.e., Creutzfeldt-Jakob disease). The authors focus on neuroimaging findings of in vivo pathology in these disorders, as well as the potential for neuroimaging to provide useful information for differential diagnosis of neurodegenerative disorders

Subcortical brain atrophy persists even in HAART-regulated HIV disease

The purpose of this study was to determine the pattern and extent of caudate nucleus and putamen atrophy in HIV-infected men with well-controlled immune status and viral replication. 155 men underwent structural brain magnetic resonance imaging; 84 were HIV-infected and 71 were uninfected controls. MRI data were processed using the Fully Deformable Segmentation routine, producing volumes for the right and left caudate nucleus and putamen, and 3-D maps of spatial patterns of thickness. There was significant atrophy in the HIV-infected men in both the caudate and putamen, principally in the anterior regions. The volume of the basal ganglia was inversely associated with the time since first seropositivity, suggesting that either there is a chronic, subclinical process that continues in spite of therapy, or that the extent of the initial insult caused the extent of atrophy

Magnetic resonance imaging In Alzheimer’s disease, mild cognitive impairment and normal aging : Multi-template tensor-based morphometry and visual rating

Alzheimer's disease (AD) is the most common neurodegenerative disease preceded by a stage of mild cognitive impairment (MCI). The structural brain changes in AD can be detected more than 20 years before symptoms appear. If we are to reveal early brain changes in AD process, it is important to develop new diagnostic methods. Magnetic resonance imaging (MRI) is an imaging technique used in the diagnosis and monitoring of neurodegenerative diseases. Magnetic resonance imaging can detect the typical signs of brain atrophy of degenerative diseases, but similar changes can also be seen in normal aging. Visual rating methods (VRM) have been developed for visual evaluation of atrophy in dementia. A computer-based tensor-based morphometry (TBM) analysis is capable of assessing the brain volume changes typically encountered in AD. This study compared the VRM and TBM analysis in MCI and AD subjects by cross-sectional and longitudinal examination. The working hypothesis was that TBM analysis would be better than the visual methods in detecting atrophy in the brain. TBM was also used to analyze volume changes in the deep gray matter (DGM). Possible associations between TBM changes and neuropsychological tests performances were examined. This working hypothesis was that the structural DGM changes would be associated with impairments in cognitive functions. In the cross-sectional study, TBM distinguished the MCI from controls more sensitively than VRM, but the methods were equally effective in differentiating AD from MCI and controls. In the longitudinal study, both methods were equally good in the evaluation of atrophy in MCI, if the groups were sufficiently large and the disease progressed to AD. Volume changes were found in DGM structures, and the atrophy of DGM structures was related to cognitive impairment in AD. Based on these results, a TBM analysis is more sensitive in detecting brain changes in early AD as compared to VRM. In addition, the study produced information about the involvement of the deep gray matter in cognitive impairment in AD.Magneettikuvaus Alzheimerin taudissa, lievässä muistihäiriössä ja normaalissa ikääntymisessä: Tensoripohjainen muotoanalyysi ja visuaalinen arviointimenetelmä Alzheimerin tauti (AT) on yleisin dementoiva sairaus, jota edeltää yleensä lievä muistitoimintojen heikentyminen. AT:n aivomuutoksia voidaan todeta yli 20 vuotta ennen sairastumista. Jotta vielä varhaisempia AT:n aivomuutoksia voidaan todeta, on tärkeää kehittää uusia diagnostisia menetelmiä. Magneettikuvausta (MK) käytetään rappeuttavien aivosairauksien diagnostiikassa ja seurannassa. MK:lla voidaan havaita aivorappeumasairauksille tyypillistä kutistumista, mutta samanlaisia muutoksia voi esiintyä myös normaalissa ikääntymisessä. Aivorappeuman arviointiin on kehitetty silmämääräisiä arviointimenetelmiä. Tietokoneperusteinen tensoripohjainen muotoanalyysi (TPM) laskee esimerkiksi AT:lle tyypillisiä aivojen tilavuusmuutoksia. Tämä tutkimus vertaili silmämääräisiä arvioitimenetelmiä ja TPM:ä lievässä muistitoimintojen heikentymisessä ja AT:ssa poikittais- ja pitkittäistutkimuksella. TPM:n oletettiin olevan silmämääräisiä menetelmiä parempi tunnistamaan aivojen kutistumismuutoksia. Lisäksi TPM:llä tutkittiin AT:iin liittyviä aivojen syvän harmaan aiheen muutoksia, joita verrattiin neuropsykologisten testien tuloksiin. Syvän harmaan aineen kutistumisen oletettiin olevan yhteydessä tietojenkäsittelyn heikentymiseen. Tulosten perustella TPM tunnisti AT:iin liittyviä aivomuutoksia silmämääräistä menetelmää paremmin jo lievän muistitoimintojen heikentymisen vaiheessa. AT:iin liittyviä aivomuutoksia löytyi myös aivojen syvästä harmaasta aineesta ja ne olivat osittain yhteydessä neuropsykologisten testien tuloksiin. Tutkimuksen perusteella TPM voi parantaa AT:n varhaisdiagnostiikkaa verrattuna silmämääräisiin arviointimenetelmiin. Tutkimus antoi myös tietoa aivojen syvän harmaan aineen osallisuudesta ihmisen tietojenkäsittelyyn

Longitudinal changes in brain structure and integrity during acute HIV

Cognitive impairment persists in the form of HIV-associated neurocognitive disorder (HAND) among chronically infected individuals despite successful viral suppression. Widespread access to combination antiretroviral therapy (cART) has allowed infected individuals to initiate treatment at an earlier time point and effectively reduce the risk of HIV-related mortality and morbidity. The current study examines whether cART, when initiated within days to weeks following infection, can longitudinally preserve brain health. Quantitative magnetic resonance image (MRI) methodologies were used to analyze T1-weighted structural images and diffusion tensor imaging (DTI) metrics. Specifically, region of interest and voxel-wise volume and tensor-based spatial statistics (TBSS) approaches were performed to evaluate differences in brain volumes and white matter microstructure. We examined 31 acute HIV (AHI) participants who had paired month 0 (baseline) and month 24 (two-year follow-up) scans. Participants were comparatively analyzed in both a longitudinal manner to themselves, and a cross-sectional manner against 25 healthy control (CO) participants. As an indication of inflammation, CD8 t-lymphocyte counts was examined as a clinical covariate. The 31 AHI participants had a median (IQR) age of 26 (23-30) years at the time of enrollment and a median (IQR) baseline CD4 count of 576 (370-868) cells/μL. All immediately initiated cART. The 25 healthy controls had a median (IQR) age of 31 (26-37) years. Differences of brain integrity in the AHI group followed longitudinally were observed. Baseline CD8 count was significantly associated with increased mean diffusivity (MD) in the longitudinally infected, present in the genu and the splenium of the corpus callosum, the corona radiata, and the superior longitudinal fasciculus (all p<0.05). Structural analysis revealed enlarged corpus callosum (p<0.01) volumes, as well as enlarged caudate and thalamus subcortical gray matter volumes in the longitudinally infected AHI participants (both p<0.05). Differences of brain integrity in the AHI group after 24 months of treatment were observed compared to healthy controls. Specifically, fractional anisotropy (FA) was reduced in AHI at 24 months compared to controls in models adjusting for age in the corpus callosum, the corona radiata, and the left superior longitudinal fasciculus (all p<0.05). Structural analyses revealed enlarged putamen and the caudate volumes (both p<0.05). We conclude that differences in both brain integrity and structural volumes can be seen in AHI with successful viral suppression when compared to healthy controls. Future work will include longitudinal imaging data from healthy controls who are followed over two-year follow-up to ensure that observed changes are disease specific. We will also comparatively investigate longitudinally treated chronic HIV-infected participants (‘positive controls’) to examine if the differences are similar to those seen when therapy is initiated in the chronic stage of infection. We will examine inflammatory plasma and CSF biomarkers to inform potential mechanisms and, separately, cognitive testing to inform clinical significance

Grey and white matter abnormalities in treated HIV-disease and their relationship to cognitive function

BACKGROUND: Long-term comorbidities such as cognitive impairment remain prevalent in otherwise effectively treated people-living-with-HIV. We investigate the relationship between cognitive impairment and brain structure in successfully treated patients using multi-modal neuroimaging from the Co-morBidity in Relation to AIDS (COBRA) cohort. METHODS: Cognitive function, brain tissue volumes and white matter microstructure were assessed in 134 HIV-positive patients and 79 controls. All patients had suppressed plasma HIV RNA at cohort entry. In addition to comprehensive voxelwise analyses of volumetric and diffusion tensor imaging, we used an unsupervised machine learning approach to combine cognitive, diffusion and volumetric data, taking advantage of the complementary information they provide. RESULTS: Compared to the highly comparable control group, cognitive function was impaired in four out of the six cognitive domains tested (median global T-scores: 50.8 vs. 54.2, p<0.001). Patients had lower grey but not white matter volumes, observed principally in regions where structure generally did not correlate with cognitive function. Widespread abnormalities in white matter microstructure were also seen, including reduced fractional anisotropy with increased mean and radial diffusivity. In contrast to the grey matter, these diffusion abnormalities correlated with cognitive function. Multivariate neuroimaging analysis identified a neuroimaging phenotype associated with poorer cognitive function, HIV-infection and systemic immune activation. CONCLUSIONS: Cognitive impairment, lower grey matter volume and white matter microstructural abnormalities were evident in HIV-positive individuals despite fully suppressive antiretroviral therapy. White matter abnormalities appear to be a particularly important determinant of cognitive dysfunction seen in well-treated HIV-positive individuals

Brain Aging in HIV-1 Infection

It has been shown that patients carrying HIV-1 accumulate damage to cells and tissues that are not directly infected by the virus itself (e.g., neurons). Importantly, these include changes known as HIV-Associated Neurodegenerative Disorder (HAND) leading to the loss of neuronal functions. HAND is an outstanding problem in the clinical management of HIV-1 patients because suppression of infectious virus by c-ART does not completely block neurodegenerative changes. Neuropsychological studies disclose cognitive alteration (such as loss of Spatial and Declarative Memory) in a substantial proportion of HIV-1 infected patients, and analysis of post-mortem brain tissues isolated from HIV-1 patients treated with c-ART show signs of neurodegeneration. In the absence of HIV-1 infection of neurons, several mechanisms have been proposed for HAND, including indirect inflammatory effects in the CNS and direct effects of viral proteins (e.g., gp120) shed from activated HIV-1-infected cells. The fact that these viral proteins enter the neurons through several pathways suggests the presence of many competing mechanisms that can contribute to HAND, each of which has its advocates. Their relative contributions to clinical disease in vivo remain to be sorted out, and this is an outstanding problem in HIV research. This chapter will shed some light on the mechanisms used by HIV-1 leading to memory impairments and premature brain aging

A T1 and DTI fused 3D corpus callosum analysis in MCI subjects with high and low cardiovascular risk profile

abstract: Understanding the extent to which vascular disease and its risk factors are associated with prodromal dementia, notably Alzheimer's disease (AD), may enhance predictive accuracy as well as guide early interventions. One promising avenue to determine this relationship consists of looking for reliable and sensitive in-vivo imaging methods capable of characterizing the subtle brain alterations before the clinical manifestations. However, little is known from the imaging perspective about how risk factors such as vascular disease influence AD progression. Here, for the first time, we apply an innovative T1 and DTI fusion analysis of 3D corpus callosum (CC) on mild cognitive impairment (MCI) populations with different levels of vascular profile, aiming to de-couple the vascular factor in the prodromal AD stage. Our new fusion method successfully increases the detection power for differentiating MCI subjects with high from low vascular risk profiles, as well as from healthy controls. MCI subjects with high and low vascular risk profiles showed differed alteration patterns in the anterior CC, which may help to elucidate the inter-wired relationship between MCI and vascular risk factors.The final version of this article, as published in NeuroImage: Clinical, can be viewed online at: http://www.sciencedirect.com/science/article/pii/S2213158216302649?via%3Dihu